Changes in Premenstrual Symptoms in Women With Schizophrenia: A Prospective Study

Choi, Seongcheol; Kang, Sang-Bum; Joe, Sook-Haeng

doi:10.1097/00006842-200109000-00016

Cited by 52 publications

(29 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have recently confirmed earlier findings of disturbed gonadal function and hypo-estrogenism in women with schizophrenia [1,27,35,39,44,[56][57][58][59][60][61]. They described menstrual irregularities and reduced blood levels of estradiol, progesterone and gonadotropins (follicle-stimulating hormone, luteinizing hormone) throughout the menstrual cycle, plus anovulation in the majority of women with schizophrenia and related psychoses.…”

Section: Hypo-estrogenism In Women With Schizophrenia (The Hypothesismentioning

confidence: 53%

See 1 more Smart Citation

Estrogens and Gonadal Function in Schizophrenia and Related Psychoses

Riecher-Rössler¹,

Kulkarni

2010

Biological Basis of Sex Differences in Psychopharmacology

View full text Add to dashboard Cite

Section: Hypo-estrogenism In Women With Schizophrenia (The Hypothesismentioning

confidence: 53%

“…For example, a more recent study [35], reported behavioural, affective and somatic symptoms of schizophrenia (not psychotic ones) to be associated with the menstrual cycle phase. Estradiol was not measured.…”

Section: Clinical Findingsmentioning

confidence: 99%

Estrogens and Gonadal Function in Schizophrenia and Related Psychoses

Riecher-Rössler¹,

Kulkarni

2010

Biological Basis of Sex Differences in Psychopharmacology

View full text Add to dashboard Cite

“…44 Schizophrenia may be an example of an underlying disorder that does not have premenstrual exacerbation of psychotic symptoms but may have superimposed affective and anxiety symptoms of PMDD. 45 The prevalence of premenstrually exacerbated axis I disorders is unknown. It is generally recommended that clinicians treat the underlying disorder first, and if premenstrual symptoms persist, subsequent daily ratings can identify PMDD.…”

Section: Epidemiologymentioning

confidence: 99%

Premenstrual Dysphoric Disorder: Burden of Illness and Treatment Update

Pearlstein¹,

Steiner²

2012

FOC

103

View full text Add to dashboard Cite

291Five percent of menstruating women have severe premenstrual symptoms and impairment of functioning defined as premenstrual dysphoric disorder (PMDD). Clinically significant premenstrual symptoms occur in at least an additional 20% of menstruating women. The diagnosis of PMDD should be confirmed by prospective symptom charting over 2 menstrual cycles to confirm the timing of the symptoms and to rule out other diagnoses. The burden of illness of PMDD includes disruption of parenting and partner relationships and decreased productivity in work roles. In addition, women with PMDD have increased use of health care services such as clinician visits and increased use of prescription medications and over-the-counter preparations. The etiology of PMDD is multifactorial. In particular, dysregulation of the serotonin and allopregnanolone systems is implicated. Several effective treatment options exist, including serotonergic antidepressant medications and an oral contraceptive that contains ethinyl estradiol and drosperinone. In addition, other hormones that suppress ovulation, anxiolytics, cognitive therapy, chasteberry and calcium may be helpful.Cinq pour cent des femmes menstruées ont des symptômes prémenstruels sévères et une incapacité du fonctionnement appelée trouble dysphorique prémenstruel (TDPM). Au moins 20 % de femmes menstruées de plus ont des symptômes prémenstruels cliniquement significatifs. Il faut confirmer le diagnostic de TDPM en suivant les symptômes de façon prospective au cours de deux cycles menstruels afin de confirmer le moment de l'apparition des symptômes et d'exclure d'autres diagnostics. Le fardeau morbide imposé par le TDPM comprend la perturbation des relations avec les enfants et le partenaire et une baisse de productivité au travail. Les femmes atteintes de TDPM ont en outre recours davantage aux services de santé comme les visites aux cliniciens et prennent davantage de médicaments d'ordonnance et en vente libre. L'étiologie du TDPM est multifactorielle. La dysrégulation des systèmes de la sérotonine et de l'allopregnanolone en particulier est mise en cause. Il existe plus d'un traitement efficace possible, y compris des antidépresseurs sérotonin-ergiques et un contraceptif oral qui contient de l'éthinyloestradiol et de la drosperinone. D'autres hormones qui bloquent l'ovulation, des anxiolytiques, la thérapie cognitive, le gattilier (Vitex agnus castus) et le calcium peuvent en outre aider. Review Paper Examen critique DiagnosisAbout 80% of women report at least mild premenstrual symptoms, 20%-50% report moderate-to-severe premenstrual symptoms, and about 5% report severe symptoms for several days with impairment of functioning.

show abstract

“…In the same line of evidence, Halonquist et al [44] observed lower psychopathology scores in schizophrenic women at the mid-luteal phase compared with the early folicular phase of the menstrual cycle. In a more recent study, however, Choi et al [45], examining the course of symptoms during the menstrual cycle in 30 inpatients with schizophrenia, found that affective and somatic symptoms worsened in the premenstrual period, but not psychotic symptoms. Recently, another research team [46] has aimed at studying this question in a sample of 50 women with schizophrenia hospitalized for an acute episode, measuring levels of estrogens, progesterone, follicle-stimulating hormone, luteinizing hormone and prolactine, and comparing with healthy controls and patients with other psychiatric diagnoses.…”

Section: Estrogenic Theorymentioning

confidence: 93%

Women and Schizophrenia: Sex-Based Pharmacotherapy

Usall¹,

Barceló²,

Márquez

2006

CPSR

View full text Add to dashboard Cite

Sex-based pharmacotherapy is a new research and clinical area which could be characterized by the inclusion of sex-related variables in clinical, research and educational issues with respect to pharmacotherapy. In this article we will review the studies that evaluate the treatment of schizophrenia with respect to sex considerations.First we will report the findings about sex differences in response to treatment: pharmacokinetic sex differences and differences in effectiveness of response to antipsychotics.We will further review the studies that evaluate the use of estrogens as an adjuvant treatment in women with schizophrenia: in patients with premenstrual worsening of symptoms or in resistant forms of the illness. Also, the possible use of raloxifene (a selective estrogen receptor modulator) as an adjuvant treatment in some postmenopausal schizophrenic women will be discussed.Finally we will review the endocrinal/sexual adverse effects of antipsychotics in women.

show abstract

Changes in Premenstrual Symptoms in Women With Schizophrenia: A Prospective Study

Abstract: The findings of this study suggest that premenstrual exacerbation of schizophrenic symptoms in female patients may not be a worsening of the schizophrenic symptoms but a concurrence of affective, behavioral, and somatic symptoms.

Cited by 52 publications

References 34 publications

Estrogens and Gonadal Function in Schizophrenia and Related Psychoses

Estrogens and Gonadal Function in Schizophrenia and Related Psychoses

Premenstrual Dysphoric Disorder: Burden of Illness and Treatment Update

Women and Schizophrenia: Sex-Based Pharmacotherapy

Contact Info

Product

Resources

About